Company intelligence / Profile preview
Reponex Pharmaceuticals
- Ownership
- Private
- Employees
- ~25
- Development stage
- Preclinical
Overview
Reponex Pharmaceuticals is a clinical-stage biopharmaceutical company focused on repositioning established drugs for new indications using innovative formulations and combinations. The company has multiple programs in Phase 2 clinical trials targeting peritonitis, chronic/complicated skin ulcers, and inflammatory bowel diseases such as Crohn’s disease and pouchitis. Their approach leverages local administration to improve efficacy while reducing systemic side effects. Recent data from proof-of-concept studies have been informative for further formulation optimization.
- Therapeutic areas
- GastroenterologyCardiovascularEndocrinologyDermatologyInfectious Diseases
- Modalities
- Small moleculeProteinCombination therapy
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Reponex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reponex Pharmaceuticals.